FDA Orders Vision-Loss Warning on Ozempic, Wegovy and Other GLP-1 Drugs

The US Food and Drug Administration has ordered a new safety warning on the labels of every GLP-1 weight-loss and diabetes drug, after concluding the medicines carry a potential increased risk of a rare eye condition that can cause sudden vision loss.

The agency announced the change on Monday in a Drug Safety Communication. It covers the entire class of glucagon-like peptide-1 receptor agonists, including Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro and Zepbound. The warning must appear in the “Warnings and Precautions” section of each product’s labelling.

The condition at the centre of the decision is non-arteritic anterior ischemic optic neuropathy, known as NAION. It occurs when blood flow to the optic nerve is reduced, and it is a common cause of sudden, painless vision loss in one eye. In some cases the damage is permanent.

What the evidence showed

The FDA said no single study settled the question. Instead, it reviewed six streams of evidence, including clinical trials, animal data, post-market surveillance, observational studies and case reports.

The largest piece was a meta-analysis of 126 randomised controlled trials covering 134,253 patients and nearly 289,000 person-years of exposure. Investigators identified 15 probable cases of NAION: 10 in patients treated with a GLP-1 drug, five in patients given a placebo and none in patients taking other glucose-lowering medicines.

Cases of NAION have now been reported after marketing for every GLP-1 drug currently sold, the agency said. The FDA put the background rate of the condition at 2.3 to 10.2 cases per 100,000 people a year among adults over 50.

Regulators in Europe moved first. Last year, the European Medicines Agency’s safety committee said NAION may affect up to 1 in 10,000 people taking semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — for at least a year. Novo Nordisk added a NAION warning to European labels for Wegovy and Ozempic in June.

What patients should do

The FDA advised prescribers to tell patients to report immediately any sudden, painless loss of vision, visual field deficit or other visual disturbance in one eye, and to refer patients with suspected NAION promptly to an ophthalmologist.

The agency stressed that the risk is described as potential, not proven, and that the warning reflects the totality of the evidence rather than a single definitive trial. Patients should not stop taking a prescribed GLP-1 drug without speaking to their clinician, the agency’s advice implies, since the medicines treat diabetes and obesity, both of which carry their own serious health risks.

The decision lands as the drugs face growing legal scrutiny. As of September, at least 4,000 consolidated claims alleged GLP-1 drugs caused vision loss, according to court records cited in trade coverage.

A class-wide decision, not a single brand

The breadth of the order is its most striking feature. Although most of the scientific and public attention has centred on semaglutide, the FDA applied the change across the whole class — from liraglutide, sold as Victoza and Saxenda, and dulaglutide, sold as Trulicity, to exenatide, the dual GIP/GLP-1 agonist tirzepatide and the oral agent orforglipron, approved earlier this year.

That matters commercially as well as clinically. GLP-1 drugs are among the best-selling medicines in the world. Wegovy pill sales alone reached $810 million in the most recent quarter reported by Novo Nordisk, and the market has become a central battleground for both drugmakers. A class-wide warning is likely to feature in prescribing conversations, in patient counselling and in the continuing litigation.

The American Academy of Ophthalmology had previously said the available evidence did not support a blanket US warning. The FDA’s decision now puts the United States in line with Europe, where the warning has been on labels for months.

The FDA’s wider safety push

The labelling change is the latest in a run of high-profile safety actions from the agency. It follows the FDA’s investigation into the gene therapy Zolgensma over tumour reports in children, and comes in the same season the regulator fast-tracked a sleep drug for children with insomnia.

Reuters reported that the FDA evaluated clinical trial data, animal data and post-market data before reaching its decision. The companies must now update their labels, and prescribers are expected to discuss the eye risk with patients starting or continuing treatment.

For the millions of Americans taking GLP-1 drugs, the practical message is narrow but important: sudden vision changes are a reason to seek urgent care, not to wait and see.